Frequency Therapeutics to Participate in September Investor and Medical Conferences streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Scientists at Frequency Therapeutics were the first to demonstrate that therapeutic concentrations of FX-322 in the human cochlea are associated with statistically significant improvements in hearing function. These clinical trials administered the therapeutic to one ear, while the other ear in the same participant was used as a control and measured the percentage of participants that exceeded an absolute 10% improvement in speech perception.
Jonas Kaufmann, Elīna Garanča et Ludovic Tézier réunis dans Parsifal francemusique.fr - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from francemusique.fr Daily Mail and Mail on Sunday newspapers.
Editas Medicine
James Mullen takes over as CEO from Feb. 15.
Editas chairman Mullen will don the CEO mantle Feb. 15, taking over for current Editas chief
Cynthia Collins. Before jumping to the Editas team, Mullen was CEO and director of the CDMO Patheon later snapped up by Thermo Fisher and also served as the CEO of Biogen. In a brief release, Editas didn’t say why Collins was leaving. “It has been a privilege to lead Editas Medicine and this extremely talented team,” she said in a statement. “I am particularly proud of the progress to the clinic we have made with both in vivo and ex vivo gene edited medicines.” Collins joined Editas in 2019, picking up the role from